CytoREductive prostAtectomy for Poly-metastatic Hormone sensiTIVE Prostate Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this clinical trial is to compare systemic therapy combined with cytoreductive prostatectomy with standard of care (SOC) in de novo poly-metastatic hormone sensitive prostate cancer (de novo pmHSPC). The main questions it aims to answer are: 1. To explore the clinical benefit and safety of systemic therapy combined with cytoreductive prostatectomy for patients with de novo pmHSPC. 2. To explore the characteristics of the subgroup of patients who could benefit more from the above treatment. 3. To explore the relationship between stage efficacy and clinical prognosis. 4. To explore the correlation between molecular imaging such as PSMA-PET/CT and its changes with treatment efficacy. Participants will undergo systemic therapy combined with cytoreductive prostatectomy. Researchers will compare systemic therapy combined with cytoreductive prostatectomy with SOC to see the pros and cons of the two strategies.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Mężczyźni w wieku 18-85 lat
- •Potwierdzony histologicznie lub cytologicznie rak prostaty
- •Rozległy nowotwór z przerzutami (5 lub więcej zmian przerzutowych)
- •Nie recepcjonowali wcześniej żadnego leczenia raka prostaty (operacyjnego ani chemioterapii)
- •Dobry ogólny stan zdrowia (wynik ECOG 0-1)
- •Prawidłowe wyniki badań krwi i funkcji wątroby/nerek
- •Pisemna zgoda na uczestnictwo w badaniu
✗ Disqualifies
- •Wcześniejsze leczenie - chemioterapia, hormono-, lub immunoterapia raka prostaty
- •Uczulenie na którykolwiek lek badawczy lub jego składniki
- •Niemożliwość wykonania badań obrazowych (CT/MRI)
- •Zawał serca, udar mózgu lub inne ciężkie choroby serca w ostatnich 6 miesiącach
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 85 Years
- Last updated (source)
- August 11, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (1)
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China
Trial contact
Liang Dong
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/12/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.